Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
HealthDay News — Heart disease continues to be a leading cause of death, according to a report from the American Heart Association published online January 27 in Circulation.
HealthDay News — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...
(HealthDay News) — There is considerable uncertainty regarding the effects of puberty blockers in young individuals experiencing gender dysphoria (GD), according to two reviews published online Jan.
The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...